{"ok":true,"entity":{"id":"vertex-pharmaceuticals","name":"Vertex Pharmaceuticals","entityType":"company","officialName":"Vertex Pharmaceuticals Incorporated","canonicalName":"Vertex Pharmaceuticals","displayName":"Vertex Pharmaceuticals","category":"バイオテクノロジー企業","shortDescription":"1989年創業、米国マサチューセッツ州ボストンに本社を置くバイオテクノロジー企業。疾患の根本原因に作用する低分子創薬を志向し、嚢胞性線維症（CFTR modulator）で事実上唯一の疾患修飾療法を提供する。近年は非オピオイド鎮痛薬Journavx、遺伝子編集療法Casgevy、1型糖尿病細胞治療へと領域を広げている。","primaryCluster":"pharmaceuticals","parentEntity":null,"verificationStatus":"draft","website":"https://www.vrtx.com","updatedAt":"2026-08-06T01:18:46.240Z","secondaryClusters":[],"alias":["Vertex"],"searchKeywords":["嚢胞性線維症","希少疾患","疼痛","1型糖尿病"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-06-001","P-01-002"]}